Natural product scaffolds as leads to drugs.

Numerous 'scaffolds' that have been identified in natural product structures have led to very significant numbers of approved drugs and drug candidates for a multiplicity of diseases over the years. In this mini-review, we discuss the base scaffolds (chemical skeletons) that we feel have produced very significant numbers of agents as drugs or drug leads and, in a number of cases, compounds that can be used as chemical synthons or that present activities in biological areas that were not obvious from their earlier history.

[1]  L. Sternbach.  The discovery of librium , 1972, Agents and Actions.

[2]  W. F. Hoffman,et al.  3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS. I. STRUCTURAL MODIFICATION OF 5-SUBSTITUTED 3,5-DIHYDROXYPENTANOIC ACIDS AND THEIR LACTONE DERIVATIVES , 1985 .

[3]  L. Sternbach,et al.  QUINAZOLINES AND 1,4-BENZODIAZEPINES. XVII. SYNTHESIS OF 1,3-DIHYDRO-5-PYRIDYL-2H-1,4-BENZODIAZEPINE DERIVATIVES. , 1964, Journal of pharmaceutical sciences.

[4]  B. White,et al.  Development, Validation, and Application of PCR Primers for Detection of Tetracycline Efflux Genes of Gram-Negative Bacteria , 2002, Applied and Environmental Microbiology.

[5]  Y. Tsujita,et al.  ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. , 1976, The Journal of antibiotics.

[6]  A. Endo.  Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. , 1979, The Journal of antibiotics.

[7]  C. Tsang,et al.  Targeting mammalian target of rapamycin (mTOR) for health and diseases. , 2007, Drug discovery today.

[8]  B. E. Evans,et al.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 1. Structural modification of 5-substituted 3,5-dihydroxypentanoic acids and their lactone derivatives. , 1985, Journal of Medicinal Chemistry.

[9]  M. Wilson,et al.  Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus. , 1990, Journal of medicinal chemistry.

[10]  Karl-Heinz Altmann,et al.  Anticancer Drugs from Nature—Natural Products as a Unique Source of New Microtubule‐Stabilizing Agents , 2007 .

[11]  Roy D. Welch,et al.  Complete genome sequence of the myxobacterium Sorangium cellulosum , 2007, Nature Biotechnology.

[12]  K. Altmann,et al.  Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. , 2008, Accounts of chemical research.

[13]  Jy Liu,et al.  A novel asymmetric synthesis of cis-3-hydroxy-4-aryl azetidin-2-ones , 1993 .

[14]  T. Chou,et al.  Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones , 2008, Proceedings of the National Academy of Sciences.

[15]  Scott J. Miller,et al.  Catalytic site-selective synthesis and evaluation of a series of erythromycin analogs. , 2008, Bioorganic & medicinal chemistry letters.

[16]  Guoqiang Wang,et al.  Synthesis of novel 6,11-O-bridged bicyclic ketolides via a palladium-catalyzed bis-allylation. , 2004, Organic letters.

[17]  E. Nogales,et al.  A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION , 1975 .

[19]  Sternbach Lh.  The discovery of librium. 1972. , 1994 .

[20]  D. A. Foster,et al.  Targeting mTOR with rapamycin: One dose does not fit all , 2009, Cell cycle.

[21]  C. Heathcock,et al.  The synthesis of mevinic acids , 1986 .

[22]  A. Ting,et al.  Protein-protein interaction detection in vitro and in cells by proximity biotinylation. , 2008, Journal of the American Chemical Society.

[23]  Yi Tang,et al.  Decoding and engineering tetracycline biosynthesis. , 2009, Metabolic engineering.

[24]  J. Clader,et al.  Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. , 1998, Journal of medicinal chemistry.

[25]  E. Lazarides,et al.  Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.

[26]  E. Abraham,et al.  The structure of cephalosporin C , 1961 .

[27]  K. Altmann,et al.  Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships. , 2008, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[28]  Wolfgang Schwede,et al.  Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. , 2006, Angewandte Chemie.

[29]  Robert J. Feeney,et al.  THE ISOLATION OF A NEW THYMINE PENTOSIDE FROM SPONGES1 , 1950 .

[30]  C. Leamon.  Folate-targeted drug strategies for the treatment of cancer. , 2008, Current opinion in investigational drugs.

[31]  D. Steinberg,et al.  Thematic review series : The Pathogenesis of Atherosclerosis An interpretive history of the cholesterol controversy , part V : The discovery of the statins and the end of the controversy 1 , 2006 .

[32]  M. Büchler,et al.  Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. , 2008, The Journal of antimicrobial chemotherapy.

[33]  B. M. Duggar.  AUREOMYCIN: A PRODUCT OF THE CONTINUING SEARCH FOR NEW ANTIBIOTICS , 1948, Annals of the New York Academy of Sciences.

[34]  D. Illingworth,et al.  3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors , 1994 .

[35]  Marilyn Roberts,et al.  Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance , 2001, Microbiology and Molecular Biology Reviews.

[36]  E. Baulieu,et al.  The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  A. Mankin,et al.  Binding Site of the Bridged Macrolides in the Escherichia coli Ribosome , 2005, Antimicrobial Agents and Chemotherapy.

[38]  J. Poehlsgaard,et al.  The bacterial ribosome as a target for antibiotics , 2005, Nature Reviews Microbiology.

[39]  S. Sehgal,et al.  Activity of rapamycin (AY-22,989) against transplanted tumors. , 1984, The Journal of antibiotics.

[40]  K. Arima,et al.  Studies on tomaymycin, a new antibiotic. I. Isolation and properties of tomaymycin. , 1972, The Journal of antibiotics.

[41]  L. Goodman,et al.  POTENTIAL ANTICANCER AGENTS.1 XL. SYNTHESIS OF THE β-ANOMER OF 9-(D-ARABINOFURANOSYL)-ADENINE , 1960 .

[42]  J. Barrish,et al.  (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential. , 2008, Journal of medicinal chemistry.

[43]  M. Kuroda,et al.  Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activity , 1976, Atherosclerosis. Supplements.

[44]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. , 1978, The Journal of antibiotics.

[45]  David J Newman,et al.  Natural products as leads to potential drugs: an old process or the new hope for drug discovery? , 2008, Journal of medicinal chemistry.

[46]  Suckling Cj,et al.  Chemical approaches to the discovery of new drugs. , 1991 .

[47]  Christopher D. Reeves,et al.  Metagenomic Analysis Reveals Diverse Polyketide Synthase Gene Clusters in Microorganisms Associated with the Marine Sponge Discodermia dissoluta , 2005, Applied and Environmental Microbiology.

[48]  O. Kandler,et al.  Towards a natural system of organisms: proposal for the domains Archaea, Bacteria, and Eucarya. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Falagas,et al.  Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. , 2008, The Journal of antimicrobial chemotherapy.

[50]  D. Siegel,et al.  Synthesis of (-)-tetracycline. , 2005, Journal of the American Chemical Society.

[51]  A. Uria,et al.  Cultivation-independent approaches to investigate the chemistry of marine symbiotic bacteria , 2009, Phytochemistry Reviews.

[52]  R. Zarivach,et al.  Structural basis for the antibiotic activity of ketolides and azalides. , 2003, Structure.

[53]  S. D. Rosa,et al.  Antiviral agents from a gorgonian,Eunicella cavolini , 1984, Experientia.

[54]  L. Sternbach,et al.  Quinazolines and 1,4-Benzodiazepines. VI.1a Halo-, Methyl-, and Methoxy-substituted 1,3-Dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones1b,c , 1962 .

[55]  W. Bergmann,et al.  Contributions to the Study of Marine Products. XL. The Nucleosides of Sponges.1 IV. Spongosine2 , 1956 .

[56]  F. Koehn.  Therapeutic potential of natural product signal transduction agents. , 2006, Current opinion in biotechnology.

[57]  B. Hearn,et al.  C-15 thiazol-4-yl analogues of (E)-9,10-didehydroepothilone D: synthesis and cytotoxicity. , 2006, Organic letters.

[58]  Magid Abou-Gharbia.  Discovery of innovative small molecule therapeutics. , 2009, Journal of medicinal chemistry.

[59]  C. Lerner,et al.  A robust platform for the synthesis of new tetracycline antibiotics. , 2008, Journal of the American Chemical Society.

[60]  P. Petersen,et al.  "Glycylcyclines". 3. 9-Aminodoxycyclinecarboxamides. , 1994, Journal of medicinal chemistry.

[61]  Epothilone, a Myxobacterial Metabolite with Promising Antitumor Activity , 2005 .

[62]  Jörn Piel,et al.  Metabolites from symbiotic bacteria. , 2009, Natural product reports.

[63]  C. Suckling.  Chemical approaches to the discovery of new drugs. , 1991, Science progress.

[64]  M. Wilson,et al.  Inhibitors of cholesterol biosynthesis. 2. 1,3,5-trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles. , 1990, Journal of medicinal chemistry.

[65]  A. Endo,et al.  Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1980, The Journal of antibiotics.

[66]  C. Hertweck,et al.  The biosynthetic logic of polyketide diversity. , 2009, Angewandte Chemie.

[67]  T. Chou,et al.  Second-generation epothilones : discovery of fludelone and its extraordinary antitumor properties , 2005 .

[68]  B. Roth,et al.  The discovery and development of atorvastatin, a potent novel hypolipidemic agent. , 2002, Progress in medicinal chemistry.

[69]  W. F. Hoffman,et al.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 3. 7-(3,5-Disubstituted [1,1'-biphenyl]-2-yl)-3,5-dihydroxy-6-heptenoic acids and their lactone derivatives. , 1986, Journal of Medicinal Chemistry.

[70]  D. Kingston,et al.  A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain. , 2000, Biochemistry.

[71]  L. Sternbach,et al.  Quinazoline 3-Oxide Structure of Compounds Previously Described in the Literature as 3.1.4-Benzoxadiazepines1 , 1960 .

[72]  K. Tatsuta,et al.  Total synthesis of selected bioactive natural products: illustration of strategy and design. , 2005, Chemical reviews.

[73]  A. Endo,et al.  Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. , 1985, Journal of medicinal chemistry.

[74]  S. Brady,et al.  An environmental DNA-derived type II polyketide biosynthetic pathway encodes the biosynthesis of the pentacyclic polyketide erdacin. , 2009, Angewandte Chemie.

[75]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[76]  T. C. Smale,et al.  CRYSTAL AND MOLECULAR STRUCTURE OF COMPACTIN, A NEW ANTIFUNGAL METABOLITE FROM PENICILLIUM BREVICOMPACTUM , 1976 .

[77]  Robert J. Feeney,et al.  CONTRIBUTIONS TO THE STUDY OF MARINE PRODUCTS. XXXII. THE NUCLEOSIDES OF SPONGES. I.1 , 1951 .

[78]  D. Teachey,et al.  Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies , 2009, British journal of haematology.

[79]  L. Bermudez,et al.  EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium , 2007, Antimicrobial Agents and Chemotherapy.

[80]  C. Hertweck,et al.  Triggering cryptic natural product biosynthesis in microorganisms. , 2009, Organic & biomolecular chemistry.

[81]  M. Pangalos,et al.  Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities , 2008, Proceedings of the National Academy of Sciences.

[82]  M. Hashimoto,et al.  Letter: Nocardicin A and B, novel monocyclic beta-lactam antibiotics from a Nocardia species. , 1976, Journal of the American Chemical Society.

[83]  A. Endo.  A gift from nature: the birth of the statins , 2008, Nature Medicine.

[84]  D. Newman,et al.  Impact of natural products on developing new anti-cancer agents. , 2009, Chemical reviews.

[85]  TatsutaKuniaki,et al.  The First Total Synthesis of Natural (−)-Tetracycline , 2000 .

[86]  P. Vagelos,et al.  Are prescription drug prices high? , 1991, Science.

[87]  E. Graziani,et al.  Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. , 2009, Natural product reports.